



## Anatara AGM 2015

11<sup>th</sup> March 2015

### Chairman's Address

I am pleased to report to Shareholders that Anatara has made significant achievements since listing on the ASX in October 2014 – just over twelve months ago. Our lead product Detach™ to control diarrhoea continues to progress towards launching on the market; large scale manufacturing is in place, we have completed our second registration clinical trial and global partnering discussions are advancing quickly. It is also pleasing to see the company rewarded by the market through its share price performance.

The company completed a well-supported capital raising of \$9 million that puts Anatara in a strong cash position to control our path forward.

We intend to maintain our initial focus on the pork industry. Pork is the most consumed meat globally, with 1.6 billion piglets weaned annually.

The first field trial involving nearly 500 piglets was successfully conducted on an Australian commercial pig farm. Detach™ almost halved the death rate among young piglets and increased the average weight of each piglet at weaning. In a second field trial, Detach™ reduced the incidence and severity of diarrhoea. A third trial is in planning. The trial results will be used as part of a registration submission to the Australian Pesticides and Veterinary Medicines Agency (APVMA). We expect Detach™ to be on the market by the first quarter of 2017.

This year we signed a Commercial Collaboration Agreement with Australia's peak pork research group, the Pork CRC. The CRC will provide Anatara with services to locate key clinical trial sites and ongoing test sites, assist with the APVMA approval of Detach™, and promote the results of these trials. Active partners and participants in the CRC include the largest Australian pork producers, feed manufacturers, farmer industry bodies and key government bodies, including the CSIRO.

Helping to drive the success of Anatara is growing concern around the world of the use and overuse of antibiotics. World health authorities are fearful that increasing antimicrobial resistance is reducing the effectiveness of antibiotics thus threatening public health.

Antibiotic resistance results from antibiotic overuse in humans and animals, with up to 80% of all antibiotics sold being used in production animals (livestock). To tackle this, authorities are increasingly banning antibiotics being used as growth promoters. Consumers are also demanding assurances their meat is safe with specific focus on 'antibiotic-free status'. Global food companies such as McDonald's are putting plans in place to supply chicken not raised on certain antibiotics. Other companies such as Subway are going further and will not supply any meat raised on any antibiotics.

cont.



For personal use only



We are seeing a fundamental shift in attitudes, creating a vacuum for non-antibiotic solutions to treat various diseases affecting livestock health along with the need to maintain optimum animal growth. This is where Anatara and Detach™ can help.

Our team are moving forward to investigate the application of Detach™ in other livestock species such as cattle and poultry. We are actively advancing discussions with the US and European regulatory authorities on the path forward to register Detach™ in those important Northern hemisphere markets.

During the year we have significantly strengthened both our board and management teams.

Your company is very much focussed on our ability to address a global problem with a new and exciting product in Detach™. We look forward to another year of success as we roll into 2016, and I look forward to keeping shareholders updated as we continue to hit our milestones.

Dr Mel Bridges  
Anatara Chairman

For personal use only

